Treatment of hypertensive patients in ambulatory care in Slovakia

Česká verzia

Authors: A. Čorejová; J. Kyselovič; E. Račanská
Authors place of work: Vedúci: prof. PharmDr. Ján Kyselovič, CSc. ; Farmaceutická fakulta ; Katedra farmakológie a toxikológie ; Univerzita Komenského v Bratislave, Slovenská republika
Published in the journal: Prakt. Lék. 2010; 90(11): 659-665
Category: Of different specialties

Summary

Blood pressure (BP) is one of the most important and common vascular risk factors, but it is often poorly controlled. The aim of the study was to obtain extensive data about the treatment and management of hypertensive patients in ambulatory care in Slovakia. We analysed a group of 910 hypertensive adult patients (age 25 – 81 years, 45.6 % males) in a retrospective study. The efficiency of the treatment was evaluated according to the four most prescribed antihypertensive drugs.

– ACE-inhibitors,

– β-blockers,

– diuretics,

– calcium channel blockers and

– positive outcomes in terms of BP reduction.

Control of the blood pressure was defined as values < 140/90 mmHg.

β-blockers were found to be the most frequently used. The majority of patients were treated with a combination of two drugs. No differences in antihypertensive efficacy among the individual antihypertensives were observed, neither when used in combination. Control of blood pressure was achieved in 28 % of patients, whereas in 20 % of patients the blood pressure did not fall under 160 and/or 100 mmHg respectively.

Out of 590 hypertensive patients that were evaluated, 41 % were obese and another 41 % of the patients were overweight.

Values of blood pressure less than 140/90 mmHg were only obtained in the group of hypertensive patients treated by calcium channel blockers monotherapy and by β-blockers + diuretics + calcium channel blockers combination.

Key words:
hypertension, control of blood pressure, drug therapy of hypertension.

Zdroje

1. Bada, V. Nová lieková forma indapamidu SR, alebo sú všetky diuretiká rovnaké? Cardiol. 2004, 13, 3, s. 150–156.

2. Borghi, C., Dormi, A.D., Addato, S. et al. Brisighela Heart Study Working Party. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J. Hypertens. 2004, 22, p. 1707-1716.

3. Borzecki, A.M., Oliveria, S.A., Berlowitz, D.R. Barriers to hypertension control. Am. Heart J. 2005, 149, p. 785–794.

4. Canzanello, V.J., Jensen, P.L., Schwartz, L.L. et al. Improved blood pressure control with a physician-nurse team and home blood pressure measurement. Mayo Clin. Proc. 2005, 80, p. 31–36.

5. Cooper, R., Cittler, J., Desvigne-Nickens, P. et al. Trends and disparities in coronary heart disease, stroke and other cardiovascular diseases in the United States: findings of the national Conference on CVD Prevention. Circulation 2001, 102, p. 3137-3147.

6. Dahlof, B., Sever, P.S., Poulter, N.R. et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005, 366, p. 895–906.

7. ESH/ESC 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007, 28, p. 1462–1536.

8. Ferreira, I., Twisk, J.W., van Mechelen, W. et al. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults. The Amsterdam Growth and Health Longitudinal Study. Arch. Intern. Med. 2005, 165, p. 42-48.

9. Fields, L.E., Burt, V.L., Cutler, J.A. et al. The burden of adult hypertension in the United States 1999 to 2000. A rising tide. Hypertension 2004, 44, p. 398-404.

10. Fodor, J.G., Lietava, J., Rieder, A. et al. Work-site hypertension prevalence and control in three Central European Countries. J. Hum. Hypertens. 2004, 18(8), p. 581-585.

11. Franklin, S.S., Pi,o J.R., Wong, N.D. et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham heart study. Circulation 2005, 111, p. 1121-1127.

12. Guidelines Commitee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003, 21, p. 1011–1053.

13. Hajjar, I.M., Kotchen, T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J. Am. Med. Assoc. 2003, 290, p. 199–206.

14. Hansson, L., Zanchetti, A., Carruthers, S.G. et al. Effects of intensive blood-pressure lowerin.g and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351, p. 1755–1762.

15. Chobanian, A.V., Bakris, G.L., Black, H.R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High blood pressure. National Heart, Lung, and Blood Institute; National High blood pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High blood pressure. Hypertension 2003, 42, p. 1206–1252.

16. Julius, S., Kjeldsen, S.E., Weber, M. et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363, p. 2022–2031.

17. Karney, P.M., Whelton, M., Reynolds, K. et al. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 2004, 22, p. 11-19.

18. Lewington, S., Clarke, R., Qizilbash, N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, p. 1903–1913.

19. Mallion, J.M., Asmar, R., Boutelant, S. et al. Twenty-four hour antihypertensive efficacy of indapamide, 1,5-Mg sustained release: results of two randomized double-blind controlled studies. J. Cardiovasc. Pharmacol. 1998, 32, p. 673-678.

20. O’Brien, E., Asmar, R., Beilin, L. et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J. Hypertens. 2003, 21, p. 821–848.

21. Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic, The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA, 2002 288, p. 2981–2997.

22. Primatesta, P., Poulter, N.R. Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J. Hypertens. 2004, 22, p. 1093-1098.

23. PROGRESS Collaborative Study Group Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358, p. 1033–1041.

24. Singer, G.M., Izhar, M., Black, H.R. Guidelines for hypertension: are quality assurance measures on target? Hypertension 2004, 43, p. 198–202.

25. Spranger, C.B., Ries, A.J., Berge, C.A. et al. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am. J. Med. 2004, 117, p. 14–18.

26. Vasan, R.S., Beiser, A., Seshadri, S. et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002, 287, p. 1003-1010.

27. Wolf-Maier, K., Cooper, R.S., Kramer, H. et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43, p. 10–17.